Lynx1 Capital Management LP bought $3.3M of Neuphoria Therapeutics (NEUP)

Executed Oct 21 2025, disclosed Oct 23 2025, 2 days later.

Value, as filed

$3.3M

639,110 sh × $5.14

Executed

Oct 21 2025

the trade date, as filed

Disclosed

Oct 23 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+0.7%

-3.3% from execution

Over the 21 trading sessions from the disclosed entry session (Oct 23 2025), the stock returned +0.7% (delay-adjusted); from the execution session (Oct 21 2025), -3.3%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

LL Lynx1 Capital Management LP 10% owner profile →

Lynx1 Capital Management LP (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Passage Bio, Inc. (PASG). Across 1 priced purchase filing, the average 21-session return was +1.5% from execution and -0.7% from disclosure (delay-adjusted; derived). The largest single filing was $854K of KRRO (77,299 sh across 3 lots, as filed), executed Oct 22.

The name

NEUP NEUP NEUP · 1 filing in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→